Skip to main content

10x Genomics Becomes First One Medical Customer to Deploy Cohort-Based COVID-19 Employee Testing

SAN FRANCISCO and PLEASANTON, Calif., May 19, 2020 (GLOBE NEWSWIRE) — Today, 10x Genomics (Nasdaq: TXG) and One Medical (Nasdaq: ONEM) announced the two organizations are partnering to pioneer a path toward the safe return to work by deploying a comprehensive approach to COVID-19 testing, digital employee symptom screening, and seamless access to remote and in-person care. 10x Genomics is the first of One Medical’s more than 7,000 employer customers to begin executing a multi-pronged, cohort-based return to the workplace strategy. 10x Genomics added One Medical as a new healthcare benefit for its employees and began offering voluntary SARS-CoV-2 PCR tests to monitor for possible infection.  As a part of the testing program, 10x Genomics has also teamed up with the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, a non-profit medical institute working on COVID-19, for clinical testing of nasal swabs.
Deemed an essential business, 10x Genomics has more than 50 academic labs, research institutes and pharmaceutical companies around the world using its products to make discoveries to accelerate the development of therapeutics, diagnostics and vaccines for battling COVID-19. These include the Vanderbilt Vaccine Center, where researchers are fast-tracking the development of antibody-based prophylaxis to protect people, particularly first responders and essential workers, who are at greatest risk of  exposure to COVID-19; Merck, which is working on identifying new viral targets for potential COVID-19 therapeutics and vaccines; and multiple labs around the world conducting research into cellular mechanisms and immune responses to infection, and other aspects of COVID-19.To continue delivering its essential products and services, 10x Genomics partnered with One Medical to deploy its workplace reentry program, Healthy Together, to quickly operationalize an open-air testing site for COVID-19 PCR nasal swab collection tests at its Pleasanton headquarters. The nasal swab tests are sent to TGen’s COVID-19 clinical laboratory for analysis. 10x Genomics already has over 150 employees from its R&D, manufacturing and IT groups enlisted in the program that are being regularly tested in cohorts. 10x Genomics plans to expand the program to cover more than 65 percent of its employee base.“The pandemic has forced us to be innovative and to forge new paths to navigate the complexities of the new workplace. We believe cohort-based testing is a powerful way, along with other recommended practices, to ensure the safety of employees,” said Ben Hindson, 10x Genomics Co-founder, President and Chief Scientific Officer.  “In One Medical, we have a partner that shared our dedication to employee health, applied a methodical science-based approach to workplace reentry and moved rapidly to operationalize the effort.”“10x Genomics is paving the way and modeling the behavior many employers should look to deploy in their organizations. By understanding the importance of broad COVID-19 testing among its employee base, they are showing that cohort-based reentry programs can work well when individuals are armed with necessary information about their COVID-19 status and are willing to use that information to support their employer’s risk mitigation efforts,” said Raj Behal, MD, MPH, One Medical Chief Quality Officer.About 10x Genomics
10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including 97 of the top 100 global research institutions and 19 of the top 20 global pharmaceutical companies, and have been cited in over 860 research papers on discoveries ranging from oncology to immunology and neuroscience. The company’s patent portfolio comprises more than 740 issued patents and patent applications.
About One Medical
One Medical is a membership-based and technology-powered primary care platform with seamless digital health and inviting in-office care, convenient to where people work, shop, live, and click. Our vision is to delight millions of members with better health and better care while reducing costs. Our mission is to transform health care for all through our human-centered, technology-powered model.
Headquartered in San Francisco, 1Life Healthcare, Inc. is the administrative and managerial services company for the affiliated One Medical physician-owned professional corporations that deliver medical services in-office and virtually. 1Life and the One Medical entities do business under the “One Medical” brand.Media Contact:
Kristina Skinner, One Medical
Director of External Communications
press@onemedical.com
(650) 743-5187
10x Genomics
media@10xgenomics.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.